PD-L1 agonistic antibodies, designed to enhance rather than block PD-1/PD-L1 interactions, have demonstrated remarkable efficacy in preclinical atherosclerosis models by reducing plaque burden and promoting lesion stability [13]. Here, CD274 is linked to atherosclerosis.